Lixte Biotechnology, Inc. (LIXT) - Gross Profit Margin

Official company branding of Lixte Biotechnology Holdings Inc. (LIXT)

Lixte Biotechnology develops inhibitors to block tumor regeneration, thereby enhancing chemotherapy. The adjusted gross margin illustrates the efficiency of these expenditures, where 0.00 represents the current metric. A lean staff of specialized experts optimizes R&D capital, while stable management led by the founders maintains fund confidence through the prudent allocation of funds during early-stage testing.

LIXT (Lixte Biotechnology, Inc.) Return on Gross Profit history from 07/04/2022 to 07/06/2026

Financial and market metric breakdowns for Lixte Biotechnology Holdings Inc. (LIXT)

Manufactured products of Lixte Biotechnology Holdings, Inc.

Developing innovative inhibitors to combat cancer requires high efficiency in managing direct costs, which determines the competitiveness of Lixte Biotechnology (LIXT). Gross margin measures the profit share after deducting production costs, allowing investors to assess the product's pricing power and operating leverage by analyzing the history of gross profitability to determine the balance between scaling and financial flexibility.